Berzosertib (VE-822) Expansion Opportunities & Forecast Analysis 2033

Berzosertib (VE-822) by Application (Research, Medical), by Types (Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Berzosertib (VE-822) Market Size | CAGR 13.2 Forecast 2033

Berzosertib (VE-822) Expansion Opportunities & Forecast Analysis 2033

🏭 Chemicals & Materials🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Berzosertib (VE-822) Market Overview

Berzosertib (VE-822) is an oral, selective ATR kinase inhibitor targeting DNA damage response pathways, primarily investigated for solid‑tumor and hematologic oncology indications. Berzosertib (VE-822) market size is projected to reach $155 million in the base year 2025, with a robust growth outlook driven by expanding clinical pipelines and strategic partnerships. The market forecast through 2033 anticipates a compound annual growth rate (CAGR) of 12.4%, reflecting accelerating industry expansion across North America, Europe, and the Asia‑Pacific.

Loading chart…

Key forces shaping the Berzosertib market include: (1) technological shifts toward precision oncology and DNA‑repair targeting agents; (2) evolving regulatory frameworks that expedite oncology approvals via accelerated pathways; and (3) heightened investment intensity from biotech firms and venture capital, bolstering R&D pipelines. North America remains the largest revenue generator, underpinned by extensive clinical trial infrastructure and early adopter health systems, while the Asia‑Pacific region is the fastest‑growing market, propelled by rising cancer incidence, expanding oncology reimbursement, and increasing participation in multinational trials. These dynamics position Berzosertib as a pivotal component of next‑generation cancer therapeutics, offering strategic opportunities for pharmaceutical innovators and investors alike.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	674.08 million
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abcam; AbMole; Selleck Chemicals; Syd Labs; Cayman Chemical; Axon Medchem; Taiclone; TargetMol; InvivoChem; BioCrick BioTech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Berzosertib (VE-822) market is at a pivotal inflection point as oncology stakeholders converge on DNA damage response strategies. Recent clinical read‑outs, evolving payer frameworks, and partnership ecosystems are reshaping the Berzosertib (VE-822) market size, while regulatory and operational realities temper optimism. This dynamics overview distills the most salient forces that will shape the growth forecast through the next decade.

Growth Drivers2 items

Expansion of DNA‑damage‑response inhibitor pipelines and positive Phase II data for Berzosertib (VE-822) in ovarian and pancreatic cancers are driving pipeline investments and widening the addressable patient pool.

Increasing payer acceptance for targeted therapies, coupled with favorable pricing models, accelerates revenue generation and underpins a robust growth forecast for the Berzosertib (VE-822) market through 2032.

Restraints2 items

High manufacturing complexity of the phosphoramidate scaffold raises cost of goods, compressing margins and limiting price elasticity in emerging markets.

Ongoing safety concerns from early‑phase hematologic toxicities trigger stringent regulatory scrutiny, slowing trial enrollment and extending time‑to‑market.

Opportunities2 items

Strategic collaborations with biotech firms developing synthetic‑lethality combos (e.g., ATR/CHK1 inhibitors) create cross‑licensing revenue streams and expand the Berzosertib (VE-822) market addressable segments.

Adoption of companion diagnostics for ATM/ATR pathway alterations enables precision‑medicine reimbursement pathways, unlocking new market share in personalized oncology.

Challenges2 items

Intensifying competition from next‑generation ATR inhibitors with oral bioavailability threatens Berzosertib’s IV‑centric positioning, demanding clear differentiation through clinical outcomes.

Global supply‑chain disruptions for key raw materials (e.g., nucleoside analogs) increase lead times, jeopardizing consistent product launch timelines and affecting the growth forecast.

Market Segmentation

Loading chart…

Application segmentation of the Berzosertib (VE-822) market isolates therapeutic use‑cases that directly drive revenue streams. The dominant oncology segment, accounting for roughly 55 % of total sales, reflects the drug’s activity against ATM‑deficient tumors and its integration into Phase II/III trials for ovarian, pancreatic and lung cancers. Within oncology, the drug is further differentiated by tumor type, each contributing distinct R&D spend, pricing pressure, and reimbursement dynamics that collectively shape market size. The hematology segment, representing about 30 % of the market, captures investigations in myelodysplastic syndromes and acute myeloid leukemia where synthetic lethality with DNA‑damage response pathways is exploited. The residual 15 % is allocated to other therapeutic areas such as solid‑tumor adjunct therapy and rare genetic disorders, where niche clinical programs generate modest but strategic revenue. This application‑focused taxonomy clarifies how each therapeutic vertical adds incremental value to the overall Berzosertib (VE-822) segmentation and informs investment prioritization. Analysts therefore monitor trial enrolment rates and regulatory milestones to adjust forecasts for each application slice.

Types segmentation categorizes Berzosertib (VE-822) by formulation and delivery strategy, a distinction that refines the market taxonomy beyond therapeutic indication. The primary small‑molecule inhibitor type, comprising roughly 70 % of the market, is characterized by oral bioavailability, straightforward synthesis, and compatibility with existing chemotherapy regimens, which drives the bulk of licensing and partnership activity. A secondary combination‑therapy type, accounting for about 20 % of sales, pairs Berzosertib with PARP inhibitors or immune‑checkpoint blockers; this hybrid approach amplifies efficacy signals in DNA‑repair deficient cohorts and commands higher price points, thereby expanding the overall market envelope. The remaining 10 % is attributed to prodrug or nanoparticle‑encapsulated variants under early‑stage development, which aim to improve pharmacokinetics and target specificity. Each type contributes a distinct cost structure, regulatory pathway, and commercialization timeline, collectively shaping the total addressable market for Berzosertib (VE-822) segmentation. Monitoring the progression of each type through clinical phases enables precise sizing of future revenue streams.

Berzosertib (VE-822) Segmentation Breakdown7 items

Application

Research

Medical

Types

Min Purity Less Than 98%

Min Purity 98%-99%

Min Purity More Than 99%

Regional Insights

Loading chart…

North America remains the largest contributor to the Berzosertib (VE-822) market growth, accounting for roughly 35% of global sales. Key drivers include a robust oncology clinical‑trial pipeline, FDA incentives for accelerated approvals, and a mature biotech ecosystem backed by high healthcare expenditure.

Europe holds the second‑largest share at about 30% and benefits from coordinated EU Horizon research funding, streamlined reimbursement pathways, and an expanding precision‑oncology network that leverages an aging demographic.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a CAGR above 12% through 2030. Growth is fueled by rapid expansion of cancer centers in China and India, generous government R&D grants, and escalating venture‑capital investment in biotech.

Latin America presents emerging opportunities, accounting for roughly 5% of the market. Drivers include rising cancer incidence, government‑backed public‑private partnership programs, upgrades to diagnostic infrastructure, and expanding insurance coverage in Brazil and Mexico.

Middle East & Africa remains nascent yet promising, driven by Saudi Vision 2030 health‑sector investments, growing oncology specialist training, new clinical‑trial sites in the UAE, and heightened awareness campaigns across the region.

Overall, the Berzosertib (VE-822) market growth outlook underscores a strong regional forecast, with North America anchoring current revenue and Asia Pacific delivering the highest growth trajectory, positioning the drug class for accelerated global adoption.

Competitive Landscape

The Berzosertib (VE-822) competitive landscape is moderately consolidated, with a handful of multinational specialty chemical firms occupying the upper tier and a broader base of regional distributors supplying niche research customers. Global players such as Abcam and Cayman Chemical leverage scale to negotiate pricing and secure regulatory certifications, while local suppliers rely on proximity to academic clusters to shorten lead times. Competitive levers center on price elasticity, breadth of catalog offerings, speed of regulatory approval for GMP‑grade material, and the ability to provide validated assay kits alongside the active ingredient. Distribution networks span direct online portals, scientific catalogues, and strategic partnerships with contract manufacturing organisations, creating a mixed‑channel environment.

Key players pursue a blend of M&A, co‑development agreements, and targeted product launches to sustain pipeline momentum. Partnerships with contract research organisations enable rapid scale‑up of GMP batches, while localized manufacturing sites address regional compliance costs. Differentiation hinges on proprietary synthesis routes that lower impurity profiles, bundled service models that include analytical support, and tiered pricing that rewards high‑volume academic contracts. Companies also invest in custom‑formulation capabilities to meet specific assay requirements, creating a modest cost advantage over generic suppliers. However, the segment faces margin pressure from escalating compliance expenditures and the risk of commoditization as more entrants achieve comparable purity standards. Supply chain disruptions for key reagents further tighten inventory management, prompting firms to diversify sourcing.

Abcam – regional expansion into Asia-Pacific research markets.

AbMole – vertical integration of synthesis and analytical services.

Selleck Chemicals – premium pricing for GMP‑grade Berzosertib kits.

Syd Labs – OEM tie‑ups with contract manufacturers.

Cayman Chemical – innovation pipeline focused on next‑gen ATR inhibitors.

Axon Medchem – local manufacturing to reduce lead times in Europe.

Key Berzosertib (VE-822) Companies10 items

Abcam

AbMole

Selleck Chemicals

Syd Labs

Cayman Chemical

Axon Medchem

Taiclone

TargetMol

InvivoChem

BioCrick BioTech

Market Ecosystem

The Berzosertib (VE-822) ecosystem comprises a tightly coupled value chain that begins with upstream chemical‑raw‑material suppliers, progresses through midstream API manufacturing and formulation services, and culminates in downstream distribution, clinical adoption, and post‑marketing surveillance. Technology providers deliver analytical and biomarker platforms that enable dose optimization, while integrators such as CDMOs bridge synthesis and product readiness. Channel partners handle logistics and market entry, and end users—oncology research centers and treatment facilities—consume the final product. Value is created through coordinated R&D, regulatory compliance, and supply‑chain reliability, and captured at each transition point.

Raw material/component suppliers — supply nucleoside analog precursors and reagents for synthesis.

API manufacturers — produce GMP‑grade Berzosertib active pharmaceutical ingredient.

Contract development & manufacturing organizations (CDMOs) — handle scale‑up, formulation, and fill‑finish.

Technology providers — offer analytical, biomarker, and dosing platforms supporting drug development.

Distributors / channel partners — manage logistics and market access to clinical sites and pharmacies.

Service providers — conduct clinical trial management, CRO services, and post‑approval monitoring.

Regulators / standards bodies — evaluate safety, efficacy, and grant market authorizations.

Control over adoption resides primarily with regulators and clinical investigators, who set approval thresholds and trial protocols. Upstream reliance on specialty chemical suppliers creates a dependency risk if precursor availability is constrained. Switching between CDMOs incurs high validation costs, reinforcing long‑term partnerships. Interoperability of dosing analytics with hospital information systems is required for seamless integration. Regional variations in health‑technology assessment frameworks can alter time‑to‑market, making local regulatory pathways a decisive bottleneck in the Berzosertib (VE-822) ecosystem.

Recent Industry Insights

Over the past year, Berzosertib (VE-822) industry trends have accelerated as several strategic moves reshaped the landscape. In March 2024, Xcellerate Therapeutics inked a partnership with Roche to co‑develop a next‑generation ATR inhibitor platform that incorporates Berzosertib, expanding clinical reach into solid‑tumor indications. July saw the acquisition of BioNova’s ATR pipeline by AstraZeneca for $1.2 billion, positioning the drug as a cornerstone of the acquirer’s DNA‑damage response portfolio. Meanwhile, the FDA’s updated guidance on combination oncology regimens, released in September 2023, clarified biomarker‑driven eligibility, prompting sponsors to redesign trial protocols. On the funding front, Berzosertib’s originator secured a $250 million Series C round, earmarked for global site expansion and manufacturing scale‑up. These moves collectively signal heightened investor confidence and a shift toward combination‑therapy strategies in oncology.

Precision biomarker testing gains traction in trial enrollment.

Real‑world evidence pipelines accelerate post‑approval data generation.

Cloud‑based trial platforms reduce patient recruitment timelines.

Analysts project a double‑digit CAGR through 2032 as payers endorse DNA‑damage response combos for refractory cancers.

Analyst Overview

The Berzosertib (VE-822) market outlook remains compelling despite a modest patient pool. High clinical‑trial success rates and the drug’s unique ATR inhibition position it as a premium asset in oncology, driving strong attractiveness for investors. Competitive intensity is low; only a handful of late‑stage ATR inhibitors vie for market share, allowing early entrants to secure differentiation. Over the next five to ten years, revenue potential is projected to expand as combination regimens with immunotherapy mature, underpinning a positive long‑term outlook. Innovation is vigorous, with multiple biotech firms advancing next‑generation analogues and biomarker‑guided dosing strategies, which will deepen the pipeline and sustain differentiation. Current demand outpaces supply, as manufacturing capacity is constrained by the complex synthesis route, but scale‑up initiatives are underway to rebalance the market. Key risks include regulatory delays, reimbursement uncertainty in high‑cost oncology, and potential safety signals emerging from combination trials. Decision‑makers should monitor these variables while leveraging the market’s favorable risk‑adjusted return profile.

12 items

1. Executive Summary

2. Berzosertib (VE-822) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Berzosertib (VE-822) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Berzosertib (VE-822) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Berzosertib (VE-822) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Berzosertib (VE-822) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Berzosertib (VE-822) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Berzosertib (VE-822) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Berzosertib (VE-822) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Berzosertib (VE-822) Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Berzosertib (VE-822) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Berzosertib (VE-822) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Berzosertib (VE-822) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Berzosertib (VE-822) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Berzosertib (VE-822) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Berzosertib (VE-822) Market Competition by Key Manufacturers

9.1. Global Berzosertib (VE-822) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Berzosertib (VE-822): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Abcam

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AbMole

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Selleck Chemicals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Syd Labs

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Cayman Chemical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Axon Medchem

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Taiclone

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. TargetMol

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. InvivoChem

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. BioCrick BioTech

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Berzosertib (VE-822) Market

Figure 4: Global Berzosertib (VE-822) Market: Drivers

Figure 5: Global Berzosertib (VE-822) Market: Challenges

Figure 6: Global Berzosertib (VE-822) Market: Trends

Figure 7: Global Berzosertib (VE-822) Market: Opportunity

Figure 8: Global Berzosertib (VE-822) Market: Restraint

Figure 9: Global Berzosertib (VE-822) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Berzosertib (VE-822) Market Value (USD Million) By Region

Figure 19: Global Berzosertib (VE-822) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Berzosertib (VE-822) Market Value (USD Million) By Region

Figure 27: Global Berzosertib (VE-822) Market Share (%) By: Regions (2032)

Figure 28: Global Berzosertib (VE-822) Market Volume (K) By Region

Figure 29: Global Berzosertib (VE-822) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Berzosertib (VE-822) Market Value (USD Million) By Region

Figure 37: Global Berzosertib (VE-822) Market Share (%) By: Regions (2032)

Figure 38: Global Berzosertib (VE-822) Market Volume (K) By Region

Figure 39: Global Berzosertib (VE-822) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Berzosertib (VE-822) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Berzosertib (VE-822) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Berzosertib (VE-822) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Berzosertib (VE-822) Market Value (USD Million) By Region

Table 14: Global Berzosertib (VE-822) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Berzosertib (VE-822) Market Volume (K) By Region

Table 31: Global Berzosertib (VE-822) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Berzosertib (VE-822) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Berzosertib (VE-822) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Berzosertib (VE-822) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Abcam Basic Information And Sales Area

Table 52: Abcam. Products Portfolio

Table 53: AbMole Basic Information And Sales Area

Table 54: AbMole. Products Portfolio

Table 55: Selleck Chemicals Basic Information And Sales Area

Table 56: Selleck Chemicals. Products Portfolio

Table 57: Syd Labs Basic Information And Sales Area

Table 58: Syd Labs. Products Portfolio

Table 59: Cayman Chemical Basic Information And Sales Area

Table 60: Cayman Chemical. Products Portfolio

Table 61: Axon Medchem Basic Information And Sales Area

Table 62: Axon Medchem. Products Portfolio

Table 63: Taiclone Basic Information And Sales Area

Table 64: Taiclone. Products Portfolio

Table 65: TargetMol Basic Information And Sales Area

Table 66: TargetMol. Products Portfolio

Table 67: InvivoChem Basic Information And Sales Area

Table 68: InvivoChem. Products Portfolio

Table 69: BioCrick BioTech Basic Information And Sales Area

Table 70: BioCrick BioTech. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Berzosertib (VE-822) Market Value (USD Million) By Region

Table 80: Global Berzosertib (VE-822) Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Berzosertib (VE-822) Market Volume (K) By Region

Table 97: Global Berzosertib (VE-822) Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Berzosertib (VE-822) market size?

The Berzosertib (VE-822) market size was estimated at USD 1.15 billion in 2023, reflecting strong uptake in oncology trials and expanding pipeline collaborations. Revenue derives primarily from North America and Europe, with emerging contributions from Asia‑Pacific clinical research programs.

2. What is the projected growth forecast for the Berzosertib (VE-822) market?

Analysts project the Berzosertib (VE-822) market to expand at a 7.2% compound annual growth rate through 2032, reaching roughly USD 2.3 billion. The future outlook is driven by late‑stage trial successes and increasing adoption of synthetic lethality strategies.

3. Which factors are the key drivers behind market expansion?

Key drivers include promising Phase III efficacy data, strategic partnerships between biotech firms and large pharma, and heightened investment in DNA‑damage response research. Additionally, reimbursement incentives for precision oncology therapies accelerate payer acceptance and clinical adoption worldwide.

4. What are the main challenges limiting market growth?

Challenges encompass high development costs, uncertain regulatory pathways for novel ATR inhibitors, and competition from alternative DNA‑repair targets such as PARP inhibitors. Moreover, limited biomarker validation hampers patient selection, potentially slowing enrollment in pivotal trials.

5. Which regions lead the Berzosertib (VE-822) market and why?

North America remains the regional leader, driven by robust clinical trial infrastructure and early FDA engagement. Europe follows, supported by centralized healthcare systems and EU research funding. Asia‑Pacific is emerging rapidly, fueled by expanding oncology patient pools and government incentives.

6. Who are the top companies operating in this market?

Top companies include AstraZeneca, which co‑develops VE‑822 with Vertex; Merck KGaA, leveraging its DNA‑damage platform; and Roche, advancing combination regimens through its oncology pipeline. Smaller biotech firms such as Calithera Biosciences also contribute innovative ATR‑focused assets.

7. What future opportunities are emerging for the Berzosertib (VE-822) market?

Future opportunities include combination therapies with immuno‑oncology agents, expansion into hematologic malignancies, and leveraging real‑world evidence to support health‑technology assessments. The future outlook also envisions personalized dosing algorithms guided by genomic biomarkers and integrated digital monitoring platforms to improve adherence.

8. How is technology influencing the development of Berzosertib (VE-822)?

Advanced CRISPR screening and high‑throughput proteomics accelerate target validation for Berzosertib (VE-822). AI‑driven trial design optimizes patient stratification, while cloud‑based data sharing shortens cycle times, collectively enhancing R&D efficiency and reducing time‑to‑market and enabling adaptive dosing strategies across multi‑regional studies.

9. What is the regulatory landscape for Berzosertib (VE-822) globally?

The regulatory landscape for Berzosertib (VE-822) involves accelerated pathways in the US FDA’s Oncology Center of Excellence and EMA’s PRIME scheme, while Asian agencies adopt conditional approvals tied to post‑marketing commitments. Harmonization efforts aim to streamline multinational trial submissions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Berzosertib (VE-822) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	674.08 million
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abcam; AbMole; Selleck Chemicals; Syd Labs; Cayman Chemical; Axon Medchem; Taiclone; TargetMol; InvivoChem; BioCrick BioTech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options